Publications by authors named "Bram Bongers"
Article Synopsis
- The study investigates the relationship between traumatic brain injury (TBI) and Alzheimer's disease (AD) by comparing AD patients with and without a history of TBI, focusing on various biomarkers in their cerebrospinal fluid (CSF).
- Researchers found no significant differences in baseline CSF biomarker levels or cognitive decline between the two groups of AD patients, suggesting that TBI may not directly affect AD progression.
- However, TBI occurring more than five years prior was linked to higher levels of specific biomarkers (NPTX2 and a trend for SNAP25), indicating possible long-term synaptic dysfunction effects when TBI occurs before the onset of AD.
Background: Clinical trials in Alzheimer's disease (AD) had high failure rates for several reasons, including the lack of biological endpoints. Fluid-based biomarkers may present a solution to measure biologically relevant endpoints. It is currently unclear to what extent fluid-based biomarkers are applied to support drug development.
View Article and Find Full Text PDFBackground: Lack of early molecular biomarkers in sporadic behavioral variants of frontotemporal dementia (bvFTD) and its clinical overlap with primary psychiatric disorders (PPD) hampers its diagnostic distinction. Synaptic dysfunction is an early feature in bvFTD and identification of specific biomarkers might improve its diagnostic accuracy. Our goal was to understand the differential diagnostic potential of cerebrospinal fluid (CSF) synaptic biomarkers in bvFTD versus PPD and their specificity towards bvFTD compared with Alzheimer's disease (AD) and controls.
View Article and Find Full Text PDF